News | January 31, 2022
Sun Pharma Q3FY22 PAT at Rs 2058.8 cr.
Sun Pharmaceutical Industries has reported consolidated financial results for the period ended December 31, 2021
Sun Pharmaceutical Industries has reported consolidated financial results for the period ended December 31, 2021
The management guided for ARV API & formulation demand to be normalised from Q4FY22 and reiterated the aspiration of US $ 1 billion in sales by FY23: ICICI Direct
The companies will continue with their exclusive agreements, including commercialization of their current portfolio
Direct to consumer pharmacy and formation as pharmacy benefit manager further mission to drastically expand access to affordable pharmaceuticals
_256_384.jpg)
The oversubscribed round was led by New York-based HOF Capital and welcomed new investors including Headline, East Ventures, MS&AD Ventures, DG Daiwa Ventures, Pioneer Fund, as well as existing investor Insignia Ventures Partners
Cipla announced its unaudited consolidated financial results for quarter ended December 31st, 2021.
The company has been manufacturing masks since the Covid-19 outbreak in 2020
Go-ahead for pivotal clinical trial which is expected to commence by March
Nuvaxovid is the first protein-based Covid-19 vaccine to receive approval for provisional registration in Australia
The extended collaboration will provide services relating to small molecules for both Forbion and BGV portfolio companies active in the biopharmaceutical space
Subscribe To Our Newsletter & Stay Updated
